Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation, a global ...

Bio-Techne Corporation (TECH) is a Minnesota-based life sciences company with a 50-year history of serving the scientific research and diagnostics industries. The company develops and supplies ...

Science Based Targets initiative validates Bio-Techne's Scope 1, 2 and 3 greenhouse gas reduction targets Market-based Scope 1 and 2 emissions reduced 49% year-over-year More than half of the ...

Bio-Techne Corporation (NASDAQ: TECH) ("Bio-Techne"), a global provider of life science tools, reagents and diagnostic products, announced that Bio-Techne shareholders voted to approve and adopt the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The approval removes one shareholder hurdle, but the transaction still depends on customary closing conditions and remaining regulatory approvals. Bio-Techne expects the deal to close in late 2026 or ...

Bio-Techne Corporation is a market leader in life science reagents, well-positioned for long-term growth in cell and gene therapeutics and organoid solutions. Despite strong fundamentals and recurring ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Merck KGaA, Darmstadt, Germany, and Bio-Techne announced they entered into a definitive agreement under which Merck KGaA will acquire Bio-Techne for $73 per share in cash. The transaction represents a ...

Bio-Techne has an average rating of hold and mean price target of $73, according to analysts polled by FactSet.

Bio-Techne’s full-year GAAP operating income surged 146% during fiscal 2026, even as adjusted operating income increased only 1%, highlighting the substantial impact that impairment charges, ...

Investment strengthens Bio-Techne's global GMP manufacturing infrastructure for cell therapy applications New Bristol facility expands GMP small molecule production capacity and complements recent ...